No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
Neoplasms, Glandular and Epithelial
Proto-Oncogene Proteins p21(ras)
rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.